Prognostic Value of Human Epididymis Protein 4 in Acute Myocardial Infarction.

IF 2.1 4区医学 Q2 MEDICINE, GENERAL & INTERNAL International Journal of General Medicine Pub Date : 2024-12-14 eCollection Date: 2024-01-01 DOI:10.2147/IJGM.S470399

Yi Tang, Wen-Yu Zhu, Si-Ling Peng, Shuai Huang, Qiu-Ni Zhao, Si-Yuan Tan, Zi-Hui Yin, Yan Zhang, Jian-Qiang Peng, Hong-Wei Pan

{"title":"Prognostic Value of Human Epididymis Protein 4 in Acute Myocardial Infarction.","authors":"Yi Tang, Wen-Yu Zhu, Si-Ling Peng, Shuai Huang, Qiu-Ni Zhao, Si-Yuan Tan, Zi-Hui Yin, Yan Zhang, Jian-Qiang Peng, Hong-Wei Pan","doi":"10.2147/IJGM.S470399","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the prognostic value of human epididymis protein 4 (HE4) in patients with acute myocardial infarction (AMI).Patients and methods: A total of 212 consecutive patients diagnosed with AMI in the Department of Cardiovascular Medicine of Hunan Provincial People's Hospital from June 2020 to May 2021 were enrolled. We determined plasma HE4 levels at baseline. The patients were followed up regularly and the occurrence of major adverse cardiac events (MACE) was recorded after discharge.Results: After a mean follow-up period of 242 (159-427) days, 67 patients had MACE. Multivariate Cox regression analysis showed that HE4 was an independent predictor of MACE in patients with AMI [HR = 1.004 (1.002-1.007), P = 0.002]. Kaplan-Meier survival curves showed that patients with HE4 levels > 532.9 pmol/L had higher MACE compared with patients with ≤ 532.9 pmol/L HE4 levels (HR=4.044, 95% CI 2.373-6.890, P <0.001). Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of HE4 for predicting MACE was 0.734 (95% CI: 0.669-0.792, P < 0.001).Conclusion: Human epididymis protein 4 (HE4) might be a novel biomarker for predicting the prognosis of patients with AMI.","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"17 ","pages":"6243-6251"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653861/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S470399","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To investigate the prognostic value of human epididymis protein 4 (HE4) in patients with acute myocardial infarction (AMI).

Patients and methods: A total of 212 consecutive patients diagnosed with AMI in the Department of Cardiovascular Medicine of Hunan Provincial People's Hospital from June 2020 to May 2021 were enrolled. We determined plasma HE4 levels at baseline. The patients were followed up regularly and the occurrence of major adverse cardiac events (MACE) was recorded after discharge.

Results: After a mean follow-up period of 242 (159-427) days, 67 patients had MACE. Multivariate Cox regression analysis showed that HE4 was an independent predictor of MACE in patients with AMI [HR = 1.004 (1.002-1.007), P = 0.002]. Kaplan-Meier survival curves showed that patients with HE4 levels > 532.9 pmol/L had higher MACE compared with patients with ≤ 532.9 pmol/L HE4 levels (HR=4.044, 95% CI 2.373-6.890, P <0.001). Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of HE4 for predicting MACE was 0.734 (95% CI: 0.669-0.792, P < 0.001).

Conclusion: Human epididymis protein 4 (HE4) might be a novel biomarker for predicting the prognosis of patients with AMI.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of General Medicine Medicine-General Medicine

自引率

0.00%

发文量

1113

审稿时长

16 weeks

期刊介绍： The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal. As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.